The Semaglutide Study

Launched by UNIVERSITY HEALTH NETWORK, TORONTO · May 17, 2024

Keywords

ClinConnect Summary

The Semaglutide Study is a clinical trial designed to understand how the medication Semaglutide affects patients who are fasting before elective surgery. The main focus is to see how often patients feel they have a "full stomach" while fasting and how the timing of their last dose of Semaglutide may influence this feeling. The study also aims to create helpful guidelines for managing patients on this medication during surgery.

To be eligible for this trial, participants must be at least 18 years old, scheduled for elective surgery at Toronto Western Hospital, and have been using Semaglutide for at least a month. However, women who are currently pregnant or individuals who have had certain types of upper gastrointestinal surgery cannot participate. Those who join the study can expect to contribute to important research that may improve care for future surgical patients on Semaglutide.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients scheduled for elective surgery at Toronto Western Hospital
• • 2. Aged ≥ 18 years of age
• • 3. American Society of Anaesthesia physical status classification I to III
• • 4. Patients being treated with Semaglutide for at least 1 month
• Exclusion Criteria:
• • 1. Current pregnancy evidenced by positive urinary pregnancy test
• • 2. Previous surgery of the upper gastrointestinal tract

Trial Officials